- RetroSense Using Optogenetics to Treat Retinitis Pigmentosa and Dry AMD
- Hemera Biosciences Obtains Initial Funding for Gene-based Treatment for AMD
- Probing to Treat Meibomian Gland Dysfunction
- Discovery About Shape of the Eye Could Boost Effectiveness of Artificial Lenses Used in Cataract Surgery
- DARPins, The Next “Game Changer” for Wet AMD?
Last week, Welch Allyn announced it has received 510(k) clearance from the FDA for the Welch Allyn iExaminer™ – a product that consists of a hardware adapter and associated iPhone app that allows healthcare providers to capture, store, send and retrieve images from the Welch Allyn PanOptic™ Ophthalmoscope using the iPhone® 4 or 4S.
Briefly, the iExaminer system consists of the following three components. The PanOptic ophthalmoscope features patented optical technology that creates a viewing area of the fundus and retinal nerve in an undilated pupil that is 5 times larger than that of a traditional ophthalmoscope and increases magnification by 26 percent to more easily see retinal details.
The iExaminer adapter aligns the optical access of the PanOptic to the visual axis of the iPhone 4 or 4S camera to capture high resolution pictures of a patient’s fundus and retinal nerve.
The iExaminer software application, available from the Apple App Store, then allows physicians to save retinal images to a patient file, as well as e-mail and print the images.
The iExaminer will be available for shipment on February 11, 2013.
The Elman Retina Group will be studying the efficacy in the use of topical Squalamine Lactate Ophthalmic Solution, 0.2% in the treatment of retinal neovascularization resulting from proliferative diabetic retinopathy.
The primary outcome measure will be the proportion of participants with complete regression of neovascularization on fundus photography at one month.
Patients will start with Squalamine one drop twice daily to the affected eye. If at one week the neovascularization shows no sign of regression, then the dose will be doubled to four times daily with a follow up at one day and one week following the increased dose frequency, then resuming the schedule at four weeks. If neovascularization returns within the study, the dose will be doubled to four times daily. In that case, a one day and one week visit will be added after increasing the dose. Squalamine treatment will discontinue after the week 20 visit.
The study is not yet recruiting participants.
Read more here.
There is no agreement concerning the best treatment for diabetic macular edema (DME). Two common options are grid laser treatment and Avastin injections.
An upcoming study in Israel currently recruiting participants will evaluate the treatment of DME using grid laser vs. intravitreal Avastin injections, as well as a combination of both therapies. The primary outcome to be measured is retinal thickness following treatments.
Click here for further details on this study on the NIH website.
Click here for a recent article in the Journal of Ophthalmology reviewing treatment options for diabetic macular edema, including monotherapies and combination therapies.
Project Glass is Google’s initiative to develop futuristic, Internet-connected glasses that show digital information right in front of your eyes, projected over the physical world, including directions, messages, and more.
Although they are not for sale quite yet, the company recently announced that it is holding events in New York City and San Fransisco where it will give software and app developers an opportunity to use the spectacles, and suggest software ideas and tie-ins. Alas, consumers will need to wait to purchase a pair.
For a video illustrating the possibilities of Google’s interactive eyewear, click here.
What do readers think? Are these glasses cool — or will they just give you a headache?
Maurie Hill, my online friend who has Stargardt’s disease (and is part of ACT’s stem cell clinical trial), just wrote about some of the low vision devices and software (all from the company she works for – Ai Squared) that aid her in her daily life. We thought it was an important topic to cover on the blog, because a lot of our readers either are visually challenged or know someone who is.
So, if you are interested in how Maurie, who is visually impaired, uses her devices and software in her daily life as a mother and wife, while holding a job, please follow this link and read her blog post on the subject.